Research Paper Volume 13, Issue 1 pp 646—674

MITF functions as a tumor suppressor in non-small cell lung cancer beyond the canonically oncogenic role

The MITF expression associated with cancer invasiveness and better outcome of NSCLC patients. (A) Heatmap of the gene expression profiles in CL1-0 and CL1-5 were presented. Each cell line was analyzed for three replicates and the significant microarray probes with 5-fold change were applied. MITF was one of the significant expressed genes. The scale was used the z-score. (B) MITF mRNA and protein level was measured by quantitative real-time PCR and immunoblot. *p C) The ratio of MITF expression in tumor and adjacent normal parts of NSCLC patients (n = 85). The scale is the base 10 logarithm of the ratio of MITF expression. The difference of MITF expression between the two groups was estimated by Wilscoxon matched-pairs test. (D) Kaplan–Meier survival analysis estimated the overall survival of NSCLC patients by the MITF expression. (E) Kaplan–Meier survival analysis estimated the disease-free survival of NSCLC patients by the MITF expression. The MITF expression of clinical specimen was measured by real-time RT-PCR with TaqMan probe. The p-value for survival was estimated by log-rank test.

Figure 1. The MITF expression associated with cancer invasiveness and better outcome of NSCLC patients. (A) Heatmap of the gene expression profiles in CL1-0 and CL1-5 were presented. Each cell line was analyzed for three replicates and the significant microarray probes with 5-fold change were applied. MITF was one of the significant expressed genes. The scale was used the z-score. (B) MITF mRNA and protein level was measured by quantitative real-time PCR and immunoblot. *p < 0.05 (mean ± SD, n = 3) (C) The ratio of MITF expression in tumor and adjacent normal parts of NSCLC patients (n = 85). The scale is the base 10 logarithm of the ratio of MITF expression. The difference of MITF expression between the two groups was estimated by Wilscoxon matched-pairs test. (D) Kaplan–Meier survival analysis estimated the overall survival of NSCLC patients by the MITF expression. (E) Kaplan–Meier survival analysis estimated the disease-free survival of NSCLC patients by the MITF expression. The MITF expression of clinical specimen was measured by real-time RT-PCR with TaqMan probe. The p-value for survival was estimated by log-rank test.